These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 27129260)

  • 1. EVI1 Interferes with Myeloid Maturation via Transcriptional Repression of Cebpa, via Binding to Two Far Downstream Regulatory Elements.
    Wilson M; Tsakraklides V; Tran M; Xiao YY; Zhang Y; Perkins AS
    J Biol Chem; 2016 Jun; 291(26):13591-607. PubMed ID: 27129260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The MDS and EVI1 complex locus (MECOM) isoforms regulate their own transcription and have different roles in the transformation of hematopoietic stem and progenitor cells.
    Maicas M; Vázquez I; Alis R; Marcotegui N; Urquiza L; Cortés-Lavaud X; Cristóbal I; García-Sánchez MA; Odero MD
    Biochim Biophys Acta Gene Regul Mech; 2017 Jun; 1860(6):721-729. PubMed ID: 28391050
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RUNX1/EVI1, which blocks myeloid differentiation, inhibits CCAAT-enhancer binding protein alpha function.
    Tokita K; Maki K; Mitani K
    Cancer Sci; 2007 Nov; 98(11):1752-7. PubMed ID: 17894555
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of EVI1 in normal and leukemic cells.
    Buonamici S; Chakraborty S; Senyuk V; Nucifora G
    Blood Cells Mol Dis; 2003; 31(2):206-12. PubMed ID: 12972028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EVI1 promotes tumor growth via transcriptional repression of MS4A3.
    Heller G; Rommer A; Steinleitner K; Etzler J; Hackl H; Heffeter P; Tomasich E; Filipits M; Steinmetz B; Topakian T; Klingenbrunner S; Ziegler B; Spittler A; Zöchbauer-Müller S; Berger W; Wieser R
    J Hematol Oncol; 2015 Mar; 8():28. PubMed ID: 25886616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The oncogene EVI1 enhances transcriptional and biological responses of human myeloid cells to all-trans retinoic acid.
    Steinmetz B; Hackl H; Slabáková E; Schwarzinger I; Smějová M; Spittler A; Arbesu I; Shehata M; Souček K; Wieser R
    Cell Cycle; 2014; 13(18):2931-43. PubMed ID: 25486480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In Vivo Deletion of the Cebpa +37 kb Enhancer Markedly Reduces Cebpa mRNA in Myeloid Progenitors but Not in Non-Hematopoietic Tissues to Impair Granulopoiesis.
    Guo H; Cooper S; Friedman AD
    PLoS One; 2016; 11(3):e0150809. PubMed ID: 26937964
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fadd and Skp2 are possible downstream targets of RUNX1-EVI1.
    Maki K; Sugita F; Nakamura Y; Sasaki K; Mitani K
    Int J Hematol; 2013 Jan; 97(1):83-91. PubMed ID: 23250858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rearrangement of the AML1/CBFA2 gene in myeloid leukemia with the 3;21 translocation: expression of co-existing multiple chimeric genes with similar functions as transcriptional repressors, but with opposite tumorigenic properties.
    Zent C; Kim N; Hiebert S; Zhang DE; Tenen DG; Rowley JD; Nucifora G
    Curr Top Microbiol Immunol; 1996; 211():243-52. PubMed ID: 8585955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Global Identification of EVI1 Target Genes in Acute Myeloid Leukemia.
    Glass C; Wuertzer C; Cui X; Bi Y; Davuluri R; Xiao YY; Wilson M; Owens K; Zhang Y; Perkins A
    PLoS One; 2013; 8(6):e67134. PubMed ID: 23826213
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The +37 kb Cebpa Enhancer Is Critical for Cebpa Myeloid Gene Expression and Contains Functional Sites that Bind SCL, GATA2, C/EBPα, PU.1, and Additional Ets Factors.
    Cooper S; Guo H; Friedman AD
    PLoS One; 2015; 10(5):e0126385. PubMed ID: 25938608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HoxA9 binds and represses the Cebpa +8 kb enhancer.
    Peng L; Guo H; Ma P; Sun Y; Dennison L; Aplan PD; Hess JL; Friedman AD
    PLoS One; 2019; 14(5):e0217604. PubMed ID: 31120998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The leukemia-associated gene MDS1/EVI1 is a new type of GATA-binding transactivator.
    Soderholm J; Kobayashi H; Mathieu C; Rowley JD; Nucifora G
    Leukemia; 1997 Mar; 11(3):352-8. PubMed ID: 9067573
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EVI1 abrogates interferon-alpha response by selectively blocking PML induction.
    Buonamici S; Li D; Mikhail FM; Sassano A; Platanias LC; Colamonici O; Anastasi J; Nucifora G
    J Biol Chem; 2005 Jan; 280(1):428-36. PubMed ID: 15519999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GATA2 haploinsufficiency accelerates EVI1-driven leukemogenesis.
    Katayama S; Suzuki M; Yamaoka A; Keleku-Lukwete N; Katsuoka F; Otsuki A; Kure S; Engel JD; Yamamoto M
    Blood; 2017 Aug; 130(7):908-919. PubMed ID: 28630119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional features of EVI1 and EVI1Δ324 isoforms of MECOM gene in genome-wide transcription regulation and oncogenicity.
    Sayadi A; Jeyakani J; Seet SH; Wei CL; Bourque G; Bard FA; Jenkins NA; Copeland NG; Bard-Chapeau EA
    Oncogene; 2016 May; 35(18):2311-21. PubMed ID: 26234679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sox4 cooperates with Evi1 in AKXD-23 myeloid tumors via transactivation of proviral LTR.
    Boyd KE; Xiao YY; Fan K; Poholek A; Copeland NG; Jenkins NA; Perkins AS
    Blood; 2006 Jan; 107(2):733-41. PubMed ID: 16204320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thrombopoietin/MPL signaling confers growth and survival capacity to CD41-positive cells in a mouse model of Evi1 leukemia.
    Nishikawa S; Arai S; Masamoto Y; Kagoya Y; Toya T; Watanabe-Okochi N; Kurokawa M
    Blood; 2014 Dec; 124(24):3587-96. PubMed ID: 25298035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repression of RUNX1 activity by EVI1: a new role of EVI1 in leukemogenesis.
    Senyuk V; Sinha KK; Li D; Rinaldi CR; Yanamandra S; Nucifora G
    Cancer Res; 2007 Jun; 67(12):5658-66. PubMed ID: 17575132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Forced expression of the leukemia-associated gene EVI1 in ES cells: a model for myeloid leukemia with 3q26 rearrangements.
    Sitailo S; Sood R; Barton K; Nucifora G
    Leukemia; 1999 Nov; 13(11):1639-45. PubMed ID: 10557037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.